Financials Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 08:50:00 12/07/2024 pm IST 5-day change 1st Jan Change
1,846 DKK +2.64% Intraday chart for Genmab A/S +5.16% -14.36%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 96,408 1,61,105 1,72,063 1,92,229 1,40,770 1,17,126 - -
Enterprise Value (EV) 1 85,618 1,45,026 1,52,725 1,69,905 1,12,635 91,238 84,915 78,243
P/E ratio 43.5 x 34.1 x 57.8 x 35.2 x 32.6 x 25.7 x 18.7 x 15 x
Yield - - - - - - - -
Capitalization / Revenue 18 x 15.9 x 20.3 x 13.2 x 8.54 x 5.91 x 4.95 x 4.16 x
EV / Revenue 16 x 14.3 x 18 x 11.6 x 6.84 x 4.6 x 3.59 x 2.78 x
EV / EBITDA 30.8 x 22.1 x 46.8 x 25.3 x 20.1 x 14.5 x 10.2 x 7.17 x
EV / FCF 68.7 x 23.7 x 77.3 x 47.3 x 16.1 x 33.7 x 14.3 x 9.14 x
FCF Yield 1.46% 4.22% 1.29% 2.12% 6.23% 2.97% 6.98% 10.9%
Price to Book 6.85 x 8.5 x 7.82 x 7.07 x 4.5 x 3.46 x 2.81 x 2.35 x
Nbr of stocks (in thousands) 65,075 65,410 65,423 65,362 65,322 63,466 - -
Reference price 2 1,482 2,463 2,630 2,941 2,155 1,846 1,846 1,846
Announcement Date 19/02/20 23/02/21 16/02/22 22/02/23 14/02/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,366 10,111 8,482 14,595 16,474 19,818 23,644 28,125
EBITDA 1 2,777 6,572 3,266 6,719 5,616 6,305 8,302 10,911
EBIT 1 2,638 6,313 3,018 6,357 5,321 5,906 7,845 10,450
Operating Margin 49.16% 62.44% 35.58% 43.56% 32.3% 29.8% 33.18% 37.16%
Earnings before Tax (EBT) 1 2,859 5,904 3,983 7,035 5,637 5,941 8,299 10,860
Net income 1 2,166 4,758 3,008 5,522 4,352 4,708 6,548 8,318
Net margin 40.37% 47.06% 35.46% 37.83% 26.42% 23.75% 27.7% 29.58%
EPS 2 34.03 72.21 45.54 83.65 66.02 71.86 98.77 123.2
Free Cash Flow 1 1,247 6,126 1,976 3,595 7,014 2,711 5,924 8,564
FCF margin 23.24% 60.59% 23.3% 24.63% 42.58% 13.68% 25.06% 30.45%
FCF Conversion (EBITDA) 44.9% 93.21% 60.5% 53.5% 124.89% 43% 71.36% 78.49%
FCF Conversion (Net income) 57.57% 128.75% 65.69% 65.1% 161.17% 57.59% 90.47% 102.96%
Dividend per Share 2 - - - - - - - -
Announcement Date 19/02/20 23/02/21 16/02/22 22/02/23 14/02/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1
Net sales 1 6,343 3,553 2,310 2,619 2,119 3,162 5,281 4,087 5,227 2,854 4,198 7,052 4,744 4,678 4,143 4,998 9,039 5,271 5,545 4,865
EBITDA 1 4,583 1,345 905 1,016 529 1,263 1,792 1,953 2,974 458 1,520 1,978 1,739 1,899 823 1,571 2,412 1,730 1,917 970
EBIT 1 4,568 1,319 890 809 514 1,247 1,761 1,931 2,665 437 1,497 1,934 1,717 1,670 801 512.2 2,229 1,638 1,772 920
Operating Margin 72.02% 37.12% 38.53% 30.89% 24.26% 39.44% 33.35% 47.25% 50.99% 15.31% 35.66% 27.42% 36.19% 35.7% 19.33% 10.25% 24.66% 31.08% 31.96% 18.91%
Earnings before Tax (EBT) 1 4,682 1,846 1,171 966 612 2,489 3,101 3,272 662 286 1,723 2,009 2,702 926 1,716 426.3 3,374 1,775 1,570 693.5
Net income 1 3,647 1,402 890 716 465 1,891 2,356 2,582 584 226 1,357 1,583 2,129 640 1,325 570.7 2,598 1,406 1,207 546.9
Net margin 57.5% 39.46% 38.53% 27.34% 21.94% 59.8% 44.61% 63.18% 11.17% 7.92% 32.32% 22.45% 44.88% 13.68% 31.98% 11.42% 28.74% 26.68% 21.77% 11.24%
EPS 2 55.52 21.25 13.47 10.82 7.050 28.66 35.71 39.17 8.820 3.430 20.61 24.03 32.32 9.670 20.18 3.757 39.51 20.37 19.25 15.38
Dividend per Share 2 - - - - - - - - - - - - - - - - - - - -
Announcement Date 12/08/20 11/08/21 10/11/21 16/02/22 11/05/22 10/08/22 10/08/22 09/11/22 22/02/23 10/05/23 03/08/23 03/08/23 07/11/23 14/02/24 02/05/24 - - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 10,790 16,079 19,338 22,324 28,135 25,888 32,211 38,883
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,247 6,126 1,976 3,595 7,014 2,711 5,924 8,564
ROE (net income / shareholders' equity) 19.6% 28.7% 14.6% 22.2% 14.8% 15.3% 16.2% 17.8%
ROA (Net income/ Total Assets) 18.4% 26.2% 13.1% 20.1% 13.3% 13.8% 14% 16.1%
Assets 1 11,803 18,143 22,885 27,453 32,704 34,081 46,849 51,641
Book Value Per Share 2 216.0 290.0 336.0 416.0 479.0 534.0 657.0 784.0
Cash Flow per Share 2 21.50 97.60 33.70 59.30 112.0 87.30 126.0 163.0
Capex 1 79 307 252 317 366 480 515 647
Capex / Sales 1.47% 3.04% 2.97% 2.17% 2.22% 2.42% 2.18% 2.3%
Announcement Date 19/02/20 23/02/21 16/02/22 22/02/23 14/02/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,846 DKK
Average target price
2,446 DKK
Spread / Average Target
+32.56%
Consensus